Novartis AG (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 158   

Articles published

NVS 67.59 -1.03 (-1.50%)
price chart
Notable Mover: Time to Buy Novartis AG (ADR) After Touching Yearly Low?
The stock of Novartis AG (ADR) (NYSE:NVS) hit a new 52-week low and has $65.46 target or 3.00% below today's $67.48 share price.
Novartis AG (ADR) Stock Was Sold By Options Traders
In today's session Novartis AG (ADR) (NVS) recorded an unusually high (654) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the January, 2017 put, expecting serious NVS decrease.
Novartis AG (ADR) (NYSE:NVS) has been downgraded to Sell in a statement by ...  Breaking Finance News
Novartis Stock Is Worth $90 A Share  Seeking Alpha
Novartis AG (ADR) (NVS) Multiple Sclerosis Molecule: Ray of Hope
Novartis AG (ADR) (NYSE:NVS) investigational molecule for the treatment and management of multiple sclerosis has shown remarkable reduction in the disease progression up to 21%.
What Will Happen to Novartis AG (ADR) Next? The Stock Just Had Huge Bearish ...
In today's session Novartis AG (ADR) (NVS) recorded an unusually high (588) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the November, 2016 put, expecting serious NVS decrease.
Rating to Follow: Is Argus Research Very Positive For Novartis AG (NYSE:NVS ...  Thorold News
Short Interest Reporting: Novartis AG (NYSE:NVS) Can't Be Less Risky ...  Post News
Novartis AG (ADR) (NVS) Acquires Selexys Pharmaceuticals Corp.
Novartis AG (ADR) (NYSE:NVS) has recently acquired Selexys Pharmaceuticals Corp. after receiving results from the SUSTAIN clinical trial, a Phase II clinical trial evaluating SelG1 for the reduction of vaso-occlusive pain among sickle cell disease (SCD ...
Exclusive: Is Selling 52-Week Stock Like Novartis AG (ADR) a Winning Strategy?  Press Telegraph
Novartis Steps Ahead in Hematology and Inflammatory Therapeutic Areas  TCC
Will Novartis AG (ADR) (NVS) Clinch Biosimilar Market by 2020?
Novartis AG's (ADR)(NYSE:NVS) biosimilar and generic division, Sandoz is working for the development of novel biosimilars versions of the blockbuster drugs to patch up the revenue loss of its blockbuster drugs' patents.
Novartis AG (ADR) (NVS) Q3 Earnings: What Leerink Expects
Leerink's 2016 EPS estimate for Novartis stands at $4.8 on revenue of $50.5 billion, compared to consensus of $4.7 and $49 billion, respectively.
Will Novartis AG (ADR) (NVS) be Forbidden in Korea after Bribe Charges?
Novartis AG (ADR) (NYSE:NVS) is hit by bad news of involvement of its six senior officials under the charges of corruption.
What Smart Money Has To Say About Novartis AG (ADR) (NVS)
Legendary investors such as Leon Cooperman and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that big brokerage houses don't publish.
Activity Reported By SEC: As Novartis A G (NVS) Market Valuation Declined ...  Chester News
Novartis AG (ADR) (NYSE:NVS) Says A Picture Is Worth A Thousand Words
Through its Canadian unit, Novartis is using images to bring out stories about advanced melanoma. The company says that the idea behind its photo campaign is to spark a conversation around advanced melanoma and to highlight the journey of patients ...
Here's What's Important With The Novartis AG (ADR) (NVS) MS Data  Insider Monkey (blog)
Novartis AG (NYSE:NVS) Fights for Survival after Patent Expiration  TCC